Drug Combination Details
| General Information of the Combination (ID: C31140) | |||||
|---|---|---|---|---|---|
| Name | Glycyrrhizin NP Info | + | lamivudine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ABCC2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | ABCC3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | ABCC4 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | ABCC5 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of glycyrrhizin and lamivudine inhibit the cisplatin efflux from the HCC cells, acting as modulators to reverse cisplatin resistance. | |||||
